ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IMCR vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Immunocore Holdings plc (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IMCR 2 — JNJ 8
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMCR VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IMCR JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% 67.90% +28.10 IMCR /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -0.93% 2.97% -3.90 JNJ /fcf-yield <GO>
Operating Margin -11.30% 34.70% -46.00 JNJ /operating-margins <GO>
Net Profit Margin -8.90% 28.50% -37.40 JNJ /net-margins <GO>
Revenue Growth (YoY) 29.00% 6.00% +23.00 IMCR /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.40 5.59 -4.19 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.8 62.1 -11.30 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.61B $662.49B -$660.88B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IMCR REV JNJ REV IMCR GROSS % JNJ GROSS % IMCR FCF JNJ FCF
FY 2025 $400.0M $94.19B 98.0% 67.9% -$15.1M $19.70B
FY 2024 $310.2M $88.82B 98.0% 69.1% $20.9M $19.84B
FY 2023 $249.4M $85.16B — — $2.9M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMCR // BETA —
JNJ // BETA 1.08